Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of IV Nafithromycin in Healthy Subjects
NCT03981887Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in community-acquired bacterial pneumonia (CAP) comparing Nafithromycin with Placebo (2 arms). Primary endpoints: Safety assessment at Day 19 and Multiple dose drug tolerability at Day 19. Started Jun 2019; status: completed.
02
Drugs
nafithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT03981887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981887.